A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors

@article{Zhao2004APL,
  title={A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors},
  author={Rongbao Zhao and Feng Gao and M. Hanscom and I. David Goldman},
  journal={Clinical Cancer Research},
  year={2004},
  volume={10},
  pages={718 - 727}
}
Whereas the major folate transporter, the reduced folate carrier (RFC), has a physiological pH optimum, transport activities for folates and antifolates have been detected with low pH optima. Because the interstitial pH in solid tumors is generally acidic, the mechanisms by which antifolates are transported at low pH could be an important determinant of drug activity under these conditions. The current study quantitated the low pH methotrexate (MTX) transport activity in human solid tumor cell… 

Figures and Tables from this paper

Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier
TLDR
It is demonstrated that RFC-independent transport in HeLa cells at low and neutral pH contributes to antifolate activity and can be diminished by antIFolate selective pressure and the loss of these activities results in marked resistance to PMX, an agent for which there is little or no loss of activity when transport mediated by RFC is abolished.
The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models
TLDR
It is concluded that BCRP transports substrate drugs more efficiently at low pH, independent of the dissociation status of the substrate.
Concentrative Transport of Antifolates Mediated by the Proton-Coupled Folate Transporter (SLC46A1); Augmentation by a HEPES Buffer
TLDR
The augmentation of intracellular pH, when cells are in a HEPES buffer, should be taken into consideration in studies that encompass all proton-coupled transporter families, and at pH levels relevant to the tumor microenvironment.
Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier
Studies were undertaken to characterize a low pH transport activity in a reduced folate carrier (RFC)-null HeLa-derived cell line (R5). This transport activity has a 20-fold higher affinity for
The molecular identity and characterization of a Proton-Coupled Folate Transporter—PCFT; biological ramifications and impact on the activity of pemetrexed—12 06 06
TLDR
The key role this transporter plays in intestinal folate absorption has been confirmed by the demonstration of a mutation in this gene in the rare autosomal recessive disorder, hereditary folate malabsorption.
Special Section on Transporters in Toxicity and Disease — Minireview The Major Facilitative Folate Transporters Solute Carrier 19 A 1 and Solute Carrier 46 A 1 : Biology and Role in Antifolate Chemotherapy of Cancer
TLDR
The molecular bases for methotrexate resistance associated with loss of RFC transport and for hereditary folate malabsorption, attributable to mutant PCFT, were determined.
Biological Role, Properties, and Therapeutic Applications of the Reduced Folate Carrier (RFC-SLC19A1) and the Proton-Coupled Folate Transporter (PCFT-SLC46A1)
TLDR
This review focuses on the facilitative pathways of (anti)folate transport, including RFC and PCFT in relation to their molecular properties, and their physiological and pharmacological roles.
Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function.
TLDR
Results indicate that in IEC-6 cells, folate transport at neutral pH is mediated predominantly by RFC; however, the folate Transport activity at pH 5.5 is RFC independent.
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor
TLDR
Pralatrexate’s enhanced activity relative to MTX is due to its much more rapid rate of transport and polyglutamation, the former less important when the carrier is saturated, and the low affinity of pralatrexates for PCFT predicts a lower level of enterohepatic circulation and increased fecal excretion of the drug relative toMTX.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities.
TLDR
Folate transport characteristics in an immortalized rat IEC-6 cell line that was found to exhibit the predominant influx activity for methotrexate (MTX) at pH 5.5 with a low level of activity at pH 7.4 indicate that RFC1 can exhibit two distinct types of folate transport activities in intestinal cells that must depend on tissue-specific modulators.
Increased Activity of a Novel Low pH Folate Transporter Associated with Lipophilic Antifolate Resistance in Chinese Hamster Ovary Cells*
TLDR
The functional importance of a low pH folate transporter that is increased when enhanced folic acid entry into cells is required as an adaptive response to antifolate selective pressure is demonstrated.
Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells.
TLDR
The results indicate that antifolate resistance in L1210/R81 cells was induced by inactivating the reduced-folate transport system and by utilizating a secondary route which has a low capacity for transporting methotrexate but whose activity is sufficient to permit cell growth in medium supplemented with folate or 5-formyltetrahydrofolate.
Contrasting effects of oncogene expression on two carrier‐mediated systems internalizing folate compounds in Fisher rat 3T3 cells
TLDR
The major route for internalization at a physiological pH of folate compounds in FR3T3 cells is by an acid pH‐dependent carrier‐mediated system independent of RFC‐1 expression and is downregulated by oncogene expression.
A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance*
TLDR
This work has shown that the more efficient folic acid uptake in CEM/MTX-LF cells resulted in a 7- and 24-fold elevated total folate pool compared with CEM and CEM-MTX cells, respectively, which conferred a novel mechanism of resistance to polyglutamatable and lipophilic antifolates by abolishing their polyglUTamylation and circumventing target enzyme inhibition.
Characterization of a Mutation in the Reduced Folate Carrier in a Transport Defective L1210 Murine Leukemia Cell Line (*)
TLDR
The MTXA line has both the mutant and the parental reduced folate carrier alleles but that expression appears to be restricted to the mutant allele, demonstrating that the methotrexate transport phenotype and resultant drug resistance in this cell line result from genetic/regulatory events at both alleles.
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
TLDR
Data indicate that MTA polyglutamation in L1210 cells is favored by both the generation of high intracellular drug levels and high MTA affinity for FPGS relative to MTX.
Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells.
TLDR
The results suggest that the cells become resistant as a result of a stable change in the transport system for MTX, but the mechanism of this process is not yet understood.
...
1
2
3
4
5
...